Join BOPA
Back to news articles

CRUK Publication update: National SACT regimen specific consent forms for HPB, Lung and Welsh adult generic forms

By BOPA on 17th October 2024

Dear BOPA memebers,

 

I am pleased to inform you that consent forms for the following groups have been reviewed and updated

 

1. Welsh generic adult SACT and immunotherapy forms

2. Hepato Pancreato Biliary (HPB) cancers – some new forms added

3. Lung cancer – some new forms added



All forms can be found here: www.cruk.org/sact_consent.


 


Best wishes,

Alia

Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|

					

				

			

		

	






	

		

			
 
				
Latest News

			

		

		

							
 
					

	
 
		By BOPA Research Committee on 27th April 2025
		
SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

		
Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…



		Read article
	


				

							
 
					

	
 
		By BOPA on 27th April 2025
		
Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

		
Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…



		Read article
	


				

							
 
					

	
 
		By BOPA Committee on 27th April 2025
		
Women for Oncology UK Spring Webinar

		
The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…



		Read article
	


				

							
 
					

	
 
		By BOPA Executive Committee on 25th April 2025
		
NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

		
BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…



		Read article